Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: A preliminary investigation

Joy M. Schmitz, Nuvan Rathnayaka, Charles E. Green, F. Gerard Moeller, Anne E. Dougherty, John Grabowski

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Two stimulant medications, modafinil and d-amphetamine, when tested individually, have shown safety and efficacy for treatment of cocaine addiction.We hypothesized that the combination of modafinil and d-amphetamine, at low doses, would show equivalent or greater benefit in reducing cocaine use compared to higher doses of each individual medication or placebo. Methods: Sixteen week, randomized, parallel-group design with four treatment arms comparing placebo to modafinil 400 mg; d-amphetamine 60 mg; modafinil 200mg plus d-amphetamine 30mg. Primary outcome variables, retention and cocaine use, were analyzed on the sample of 73 participants who received the first dose of the study medication. Results:Retention rates did not differ between groups andwere generally low, with 40% remaining in treatment at week 12 and 20% at week 16. Participants receiving the combination of modafinil and d-amphetamine showed a trend of increased cocaine use over time with a corresponding low Bayesian probability of benefit (33%). Relatively better cocaine outcomes were observed in the placebo and d-amphetamine only groups.The study medications were generally well-tolerated with few adverse effects, yet rates of adherencewere suboptimal (≤80%). Conclusion: Data from this preliminary investigation fail to provide evidential support for conducting a larger study of this dual-agonist medication combination for treatment of cocaine dependence.

Original languageEnglish (US)
Article numberArticle 77
JournalFrontiers in Psychiatry
Volume3
Issue numberAUG
DOIs
StatePublished - Oct 4 2012

Fingerprint

Cocaine-Related Disorders
Dextroamphetamine
Cocaine
Placebos
Therapeutics
modafinil
Safety

Keywords

  • Clinical trial
  • Cocaine dependence
  • D-amphetamine
  • Modafinil

Cite this

Combination of modafinil and d-amphetamine for the treatment of cocaine dependence : A preliminary investigation. / Schmitz, Joy M.; Rathnayaka, Nuvan; Green, Charles E.; Moeller, F. Gerard; Dougherty, Anne E.; Grabowski, John.

In: Frontiers in Psychiatry, Vol. 3, No. AUG, Article 77, 04.10.2012.

Research output: Contribution to journalArticle

Schmitz, Joy M. ; Rathnayaka, Nuvan ; Green, Charles E. ; Moeller, F. Gerard ; Dougherty, Anne E. ; Grabowski, John. / Combination of modafinil and d-amphetamine for the treatment of cocaine dependence : A preliminary investigation. In: Frontiers in Psychiatry. 2012 ; Vol. 3, No. AUG.
@article{ae2ce4d6ccb64e4182d12f76e05bdb9b,
title = "Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: A preliminary investigation",
abstract = "Background: Two stimulant medications, modafinil and d-amphetamine, when tested individually, have shown safety and efficacy for treatment of cocaine addiction.We hypothesized that the combination of modafinil and d-amphetamine, at low doses, would show equivalent or greater benefit in reducing cocaine use compared to higher doses of each individual medication or placebo. Methods: Sixteen week, randomized, parallel-group design with four treatment arms comparing placebo to modafinil 400 mg; d-amphetamine 60 mg; modafinil 200mg plus d-amphetamine 30mg. Primary outcome variables, retention and cocaine use, were analyzed on the sample of 73 participants who received the first dose of the study medication. Results:Retention rates did not differ between groups andwere generally low, with 40{\%} remaining in treatment at week 12 and 20{\%} at week 16. Participants receiving the combination of modafinil and d-amphetamine showed a trend of increased cocaine use over time with a corresponding low Bayesian probability of benefit (33{\%}). Relatively better cocaine outcomes were observed in the placebo and d-amphetamine only groups.The study medications were generally well-tolerated with few adverse effects, yet rates of adherencewere suboptimal (≤80{\%}). Conclusion: Data from this preliminary investigation fail to provide evidential support for conducting a larger study of this dual-agonist medication combination for treatment of cocaine dependence.",
keywords = "Clinical trial, Cocaine dependence, D-amphetamine, Modafinil",
author = "Schmitz, {Joy M.} and Nuvan Rathnayaka and Green, {Charles E.} and Moeller, {F. Gerard} and Dougherty, {Anne E.} and John Grabowski",
year = "2012",
month = "10",
day = "4",
doi = "10.3389/fpsyt.2012.00077",
language = "English (US)",
volume = "3",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Research Foundation",
number = "AUG",

}

TY - JOUR

T1 - Combination of modafinil and d-amphetamine for the treatment of cocaine dependence

T2 - A preliminary investigation

AU - Schmitz, Joy M.

AU - Rathnayaka, Nuvan

AU - Green, Charles E.

AU - Moeller, F. Gerard

AU - Dougherty, Anne E.

AU - Grabowski, John

PY - 2012/10/4

Y1 - 2012/10/4

N2 - Background: Two stimulant medications, modafinil and d-amphetamine, when tested individually, have shown safety and efficacy for treatment of cocaine addiction.We hypothesized that the combination of modafinil and d-amphetamine, at low doses, would show equivalent or greater benefit in reducing cocaine use compared to higher doses of each individual medication or placebo. Methods: Sixteen week, randomized, parallel-group design with four treatment arms comparing placebo to modafinil 400 mg; d-amphetamine 60 mg; modafinil 200mg plus d-amphetamine 30mg. Primary outcome variables, retention and cocaine use, were analyzed on the sample of 73 participants who received the first dose of the study medication. Results:Retention rates did not differ between groups andwere generally low, with 40% remaining in treatment at week 12 and 20% at week 16. Participants receiving the combination of modafinil and d-amphetamine showed a trend of increased cocaine use over time with a corresponding low Bayesian probability of benefit (33%). Relatively better cocaine outcomes were observed in the placebo and d-amphetamine only groups.The study medications were generally well-tolerated with few adverse effects, yet rates of adherencewere suboptimal (≤80%). Conclusion: Data from this preliminary investigation fail to provide evidential support for conducting a larger study of this dual-agonist medication combination for treatment of cocaine dependence.

AB - Background: Two stimulant medications, modafinil and d-amphetamine, when tested individually, have shown safety and efficacy for treatment of cocaine addiction.We hypothesized that the combination of modafinil and d-amphetamine, at low doses, would show equivalent or greater benefit in reducing cocaine use compared to higher doses of each individual medication or placebo. Methods: Sixteen week, randomized, parallel-group design with four treatment arms comparing placebo to modafinil 400 mg; d-amphetamine 60 mg; modafinil 200mg plus d-amphetamine 30mg. Primary outcome variables, retention and cocaine use, were analyzed on the sample of 73 participants who received the first dose of the study medication. Results:Retention rates did not differ between groups andwere generally low, with 40% remaining in treatment at week 12 and 20% at week 16. Participants receiving the combination of modafinil and d-amphetamine showed a trend of increased cocaine use over time with a corresponding low Bayesian probability of benefit (33%). Relatively better cocaine outcomes were observed in the placebo and d-amphetamine only groups.The study medications were generally well-tolerated with few adverse effects, yet rates of adherencewere suboptimal (≤80%). Conclusion: Data from this preliminary investigation fail to provide evidential support for conducting a larger study of this dual-agonist medication combination for treatment of cocaine dependence.

KW - Clinical trial

KW - Cocaine dependence

KW - D-amphetamine

KW - Modafinil

UR - http://www.scopus.com/inward/record.url?scp=84866881391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866881391&partnerID=8YFLogxK

U2 - 10.3389/fpsyt.2012.00077

DO - 10.3389/fpsyt.2012.00077

M3 - Article

C2 - 22969732

AN - SCOPUS:84866881391

VL - 3

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

IS - AUG

M1 - Article 77

ER -